Retrospective Collection of Effectiveness and Safety Data From Patients Treated With Liraglutide or DPP-4 Inhibitor in Primary Care in Europe

Sponsor
Novo Nordisk A/S
Study ID
NCT01890993
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • liraglutide — DRUG
    Anonymised patient level data will be collected by the patients' own general practitioner and electronic case report form (eCRF) will be used to capture the data.

Study Details

This study is conducted in Europe. The aim of this study is to demonstrate the clinical effectiveness and safety of liraglutide and dipeptidyl peptidase-4 (DPP-4) inhibitor therapy in routine primary care in Europe.

Key Dates

Start date
Aug 31, 2013
Status verified
May 2015
Primary completion
Jun 30, 2014
Completion
Jun 30, 2014

Study Design

Enrollment
952 participants (actual)

Arms

  • Arm: Liraglutide
  • Arm: DPP-4

Primary Outcome Measure

Change in HbA1c (glycosylated haemoglobin) [ Time Frame: Baseline (anytime within 3 months before therapy initiation), month 12 (+/-2) ]

Related Studies